Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Jiangsu HengRui Medicine Co: Clinical Trials & FDA Approval Profile

Jiangsu HengRui Medicine Co (Global / Institutional) sponsors 232 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 71 active protocols (42 recruiting now), 77 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)10.3%
Median Closed Enrollment vs National (145 pts)187 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Jiangsu HengRui Medicine Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)232
Active Pipeline (Recruiting Now)71 (42)
Completed vs Stopped Early77 / 24 (10.3%)
Median Closed Actual Enrollment187 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Jiangsu HengRui Medicine Co
Hospital Research SiteLocationShared Protocols
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality24
Beijing Cancer HospitalBeijing, Beijing Municipality14
Zhejiang Cancer HospitalHangzhou, Zhejiang12

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Jiangsu HengRui Medicine Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07286032A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced ThrombocytopeniaPhase IIIRECRUITING
NCT03588091Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast CancerPhase IIICOMPLETED
NCT04447118Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed PlatinPhase IIICOMPLETED
NCT04300114A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line PlaPhase IIITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the Jiangsu HengRui Medicine Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI